G1 Therapeutics (NASDAQ:GTHX) Rating Increased to Hold at Zacks Investment Research

Share on StockTwits

G1 Therapeutics (NASDAQ:GTHX) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Saturday, Zacks.com reports.

According to Zacks, “G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel, small-molecule therapies which address significant unmet needs in the treatment of cancer. The company’s product pipeline consists of CDK4/6, Trilaciclib (G1T28), G1T38 and G1T48. G1 Therapeutics, Inc. is based in Research Triangle Park, NC. “

Other research analysts have also recently issued research reports about the stock. ValuEngine raised shares of G1 Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Cowen reaffirmed a “buy” rating on shares of G1 Therapeutics in a research report on Wednesday. JPMorgan Chase & Co. raised shares of G1 Therapeutics from a “neutral” rating to an “overweight” rating and upped their target price for the company from $38.00 to $45.00 in a research report on Thursday, August 8th. HC Wainwright reaffirmed a “buy” rating and issued a $72.00 target price on shares of G1 Therapeutics in a research report on Wednesday. Finally, B. Riley set a $55.00 target price on shares of G1 Therapeutics and gave the company a “buy” rating in a research report on Friday, September 27th. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $56.67.

NASDAQ GTHX opened at $23.68 on Friday. The firm’s 50-day moving average is $24.51 and its two-hundred day moving average is $26.43. G1 Therapeutics has a 12 month low of $13.87 and a 12 month high of $46.50. The stock has a market capitalization of $839.76 million, a P/E ratio of -9.25 and a beta of 2.21.

G1 Therapeutics (NASDAQ:GTHX) last posted its earnings results on Tuesday, November 5th. The company reported ($0.86) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.87) by $0.01. On average, equities research analysts anticipate that G1 Therapeutics will post -3.29 EPS for the current fiscal year.

Institutional investors and hedge funds have recently modified their holdings of the company. Bank of Montreal Can lifted its position in shares of G1 Therapeutics by 93,600.0% during the second quarter. Bank of Montreal Can now owns 2,811 shares of the company’s stock worth $86,000 after purchasing an additional 2,808 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. lifted its position in shares of G1 Therapeutics by 18.8% during the second quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,166 shares of the company’s stock worth $97,000 after purchasing an additional 500 shares in the last quarter. Hodges Capital Management Inc. acquired a new stake in shares of G1 Therapeutics during the second quarter worth about $235,000. Abbot Financial Management Inc. acquired a new stake in shares of G1 Therapeutics during the second quarter worth about $262,000. Finally, State Board of Administration of Florida Retirement System acquired a new stake in shares of G1 Therapeutics during the second quarter worth about $399,000. 76.63% of the stock is currently owned by institutional investors and hedge funds.

G1 Therapeutics Company Profile

G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/II clinical trials for patients with extensive-stage small cell lung cancer, as well as Phase II clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase Ib/IIa clinical trials for the treatment of breast cancer and in Phase Ib/II clinical trial for non-small cell lung cancer; and G1T48, an oral selective estrogen receptor degrader, which is in Phase I clinical trial.

Further Reading: Market Capitalization – What it Means for Investors

Get a free copy of the Zacks research report on G1 Therapeutics (GTHX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for G1 Therapeutics (NASDAQ:GTHX)

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.